Articles

Long-term follow-up data of a phase 2 study confirmed the extended prognosis of ibrutinib-treated patients with CLL, particularly those with TP53 alterations. Read More ›

Longer follow-up data of the randomized, phase 3 ALPINE study confirmed PFS benefit and more favorable cardiac safety profile of zanubrutinib compared to ibrutinib therapy in patients with R/R CLL/SLL, with emergence of no new safety signals. Read More ›

Results of the phase 2 CLL2-BAAG trial showed that MRD-guided triple combination therapy of acalabrutinib, venetoclax and obinutuzumab yielded better efficacy outcomes, deeper remission, and achievement of uMRD in patients with R/R CLL. Read More ›

Data from an ongoing, first-in-human phase 1/2 study suggests that combination sonrotoclax (160 mg and 320 mg) plus zanubrutinib therapy was well tolerated and showed encouraging anti-leukemic activity in patients with treatment-naive CLL/SLL. Read More ›

Retrospective study of patients with HR+/HER2− metastatic breast cancer with bone-only metastases and pre-clinical data finds CDK4/6 inhibitors not as effective as in patients with metastases to other body sites. Read More ›

The development of action plans by providers and use of educational sessions found to improve patient compliance with oral oncolytics for those with HR+/HER2− breast cancer. Read More ›

Real-world analysis finds a preference shift from palbociclib to ribociclib and no significant differences in time to next treatment or time to treatment discontinuation for patients with HR+/HER-metastatic breast cancer. Read More ›

Study finds that patients with ER+/HER2− metastatic breast cancer who have prior CDK4/6 inhibitor treatment have a greater PFS when treated with elacestrant compared to standard of care. Read More ›

Oncology nurse navigators who work with younger patients with breast cancer and patients with metastatic breast cancer report barriers to services, information, and referrals. Read More ›

The phase 3 HER2CLIMB-02 trial demonstrated significant prolongation of progression-free survival with tucatinib plus ado-trastuzumab emtansine combination therapy in patients with previously treated HER2+ metastatic breast cancer (MBC). Read More ›